OJJAARA DIN 02552981
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Available to quote
Health Canada record
| Active ingredient(s) | MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) 200 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EJ04 MOMELOTINIB |
| Original market date | 21-Jan-2025 |
| Current status date | 21-Jan-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02552965 | OJJAARA | GLAXOSMITHKLINE INC | Tablet | MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) 100 MG | Marketed |
| 02552973 | OJJAARA | GLAXOSMITHKLINE INC | Tablet | MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) 150 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34353 | 2024-11-08 | New Drug Submission (NDS) |